|Bid||4.5000 x 900|
|Ask||4.6100 x 800|
|Day's Range||4.5170 - 4.6850|
|52 Week Range||3.8700 - 10.4900|
|Beta (3Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Yahoo Finance's Seana Smith and Adam Shapiro talks to Vered Caplan, CEO of Orgenesis, about making it to the top in a male-dominated field, and how her company is making a name for itself in the world of biotechnology.
Taking the occasional loss comes part and parcel with investing on the stock market. Unfortunately, shareholders of Orgenesis Inc. (NASDAQ:ORGS) have suffered share price declines over the last year. The share price is down a...
Orgenesis Inc. (ORGS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In 2013 Vered Caplan was appointed CEO of Orgenesis Inc. (NASDAQ:ORGS). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will consider theRead More...
If you own shares in Orgenesis Inc (NASDAQ:ORGS) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...
I am going to take a deep dive into Orgenesis Inc’s (NASDAQ:ORGS) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structure isRead More...
If you are looking to invest in Orgenesis Inc’s (NASDAQ:ORGS), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...